1. Introduction
===============

Many recent studies about the discovery of versatile structures and bioactivities of eunicellin-type compounds isolated from soft corals have been reported \[[@B1-marinedrugs-11-02741],[@B2-marinedrugs-11-02741],[@B3-marinedrugs-11-02741],[@B4-marinedrugs-11-02741],[@B5-marinedrugs-11-02741],[@B6-marinedrugs-11-02741],[@B7-marinedrugs-11-02741],[@B8-marinedrugs-11-02741],[@B9-marinedrugs-11-02741],[@B10-marinedrugs-11-02741],[@B11-marinedrugs-11-02741],[@B12-marinedrugs-11-02741],[@B13-marinedrugs-11-02741],[@B14-marinedrugs-11-02741],[@B15-marinedrugs-11-02741]\]. The soft coral *Cladiella krempfi* has been found to generate several types of metabolites including eunicellin-type diterpenoids \[[@B16-marinedrugs-11-02741],[@B17-marinedrugs-11-02741]\] and pregnane-type steroids \[[@B18-marinedrugs-11-02741],[@B19-marinedrugs-11-02741],[@B20-marinedrugs-11-02741]\]. Our previous study on the bioactive secondary metabolites of a Taiwanese soft coral *Cladiella krempfi* also resulted in the isolation of a series of new eunicellin-based diterpenoids, krempfielins A--I \[[@B21-marinedrugs-11-02741],[@B22-marinedrugs-11-02741]\]. In this paper, we further report the discovery of four new eunicellin-based diterpenoids, krempfielins J--M (**1**--**4**), along with two known diterpenoids sclerophytin F (**5**) \[[@B23-marinedrugs-11-02741]\] and litophynol B (**6**) \[[@B24-marinedrugs-11-02741]\] ([Chart 1](#marinedrugs-11-02741-f003){ref-type="fig"}). The ability of these compounds to inhibit the superoxide anion generation and elastase release in FMLP/CB-induced human neutrophils was also evaluated. The results showed that at 10 μM compounds **2** and **4** effectively inhibited the elastase release in FMLP/CB-induced human neutrophils.

![Structures of metabolites **1**--**6**.](marinedrugs-11-02741-g003){#marinedrugs-11-02741-f003}

2. Results and Discussion
=========================

Krempfielin J (**1**) showed the pseudomolecular ion peak \[M + Na\]^+^ at *m*/*z* 417.2616 in the HRESIMS and the molecular formula was determined as C~23~H~38~O~5~. NMR spectroscopic data of **1** ([Table 1](#marinedrugs-11-02741-t001){ref-type="table"}) showed the presence of one acetoxy group (δ~C~ 169.6 and 22.4; δ~H~ 2.12, s, 3H) and one methoxyl group (δ~C~ 57.0 and δ~H~ 3.34, 3H, s). The NMR data of **1** was found to be similar to the known compound, **7** \[[@B22-marinedrugs-11-02741],[@B25-marinedrugs-11-02741]\] ([Chart 1](#marinedrugs-11-02741-f003){ref-type="fig"}). Comparison of the NMR data of them revealed that the only difference between both compounds arises from the replacement of the *n*-butyryloxy group at C-3 in **7** by one acetoxy group in **1**. The stereochemistry of **1** was confirmed by comparison of the NMR data and NOE correlations of both **7** and **1**.
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###### 

^13^C and ^1^H NMR data for compounds **1**--**4**.

                    1 ^a^             2 ^b^          3 ^a^              4 ^a^                                                       
  ----------------- ----------------- -------------- ------------------ -------------- -------------- -------------- -------------- --------------
  1                 45.6, CH ^c^      2.20 dd        37.8, CH           3.24 m         44.2, CH       2.31 t (8.0)   44.2, CH       2.31 ddd
  (10.8, 8.0) ^d^   (8.0, 6.0, 2.0)                                                                                                 
  2                 92.1, CH          3.59 br s      80.9, CH           3.58 m         90.4, CH       3.69 br s      90.2, CH       3.69 d (2.0)
  3                 86.6, C                          83.8, C                           86.6, C                       86.6, C        
  4                 36.8, CH~2~       1.75 m         28.8, CH~2~        1.92 m         34.6, CH~2~    1.94 m         34.9, CH~2~    1.92 m
  2.61 dd           2.90 dd           2.48 m         2.52 dd                                                                        
  (14.4, 9.2)       (14.8, 7.0)       (14.8, 8.8)                                                                                   
  5                 26.8, CH~2~       1.33 m         19.9, CH~2~        1.50 m         30.4, CH~2~    1.42 m         30.5, CH~2~    1.45 m
  1.59 m            1.71 m            1.71 m         1.68 m                                                                         
  6                 90.6, CH          4.12 d (6.0)   70.1, CH           3.68 m         79.0, CH       4.57 d (8.4)   79.1, CH       4.58 d (7.2)
  7                 75.9, C                          75.5, C                           76.6, C                       76.5, C        
  8                 45.0, CH~2~       1.82 m         79.0, CH           3.62 m         46.0, CH~2~    1.85 m         45.9, CH~2~    1.83 m
  9                 78.5, CH          4.18 dd        69.9, CH           4.39 t (8.0)   79.4, CH       4.53 m         78.8, CH       4.40 m
  (14.8, 7.2)                                                                                                                       
  10                53.9, CH          2.95 t (7.2)   50.0, CH           2.51 br s      51.0, CH       2.86 m         51.4, CH       2.93 dd
  (7.2, 6.0)                                                                                                                        
  11                147.6, C                         145.3, C                          148.0, C                      143.0, C       
  12                31.5, CH~2~       2.04 m         71.6, CH           5.29 m         70.7, CH       4.37 s         72.5, CH       5.44 dd
  2.25 m            (5.6, 2.8)                                                                                                      
  13                24.6, CH~2~       1.00 m         31.9, CH~2~        1.58 m         31.2, CH~2~    1.46 m         29.0, CH~2~    1.42 m
  1.70 m            2.17 m            1.84 m         1.90 m                                                                         
  14                44.0, CH          1.26 m         40.1, CH           1.48 m         36.5, CH       1.82 m         37.2, CH       1.70 m
  15                23.1, CH~3~       1.41 s         26.3, CH~3~        1.56 s         23.2, CH~3~    1.48 s         23.2, CH~3~    1.47 s
  16                23.6, CH~3~       1.13 s         13.7, CH~3~        1.19 s         22.6, CH~3~    1.17 s         22.8, CH~3~    1.18 s
  17                109.4, CH~2~      4.64 s         105.0, CH~2~ ^e^   5.04 s         111.8, CH~2~   4.87 s         114.9, CH~2~   4.97 s
  4.68 s            5.23 s            5.06 s         5.14 s                                                                         
  18                29.1, CH          1.72 m         28.3, CH           2.03 m         29.0, CH       1.80 m         28.9, CH       1.80 m
  19                15.6, CH~3~       0.79 d (6.8)   21.5, CH~3~        1.06 d (6.5)   16.4, CH~3~    0.85 d (6.4)   16.2, CH~3~    0.83 d (6.8)
  20                21.9, CH~3~       0.97 d (6.8)   21.5, CH~3~        1.09 d (6.5)   21.9, CH~3~    1.00 d (6.4)   21.8, CH~3~    0.96 d (6.8)
  3-*n*-butyrate                                     172.6, C                                                                       
  37.5, CH~2~       2.22 m                                                                                                          
  2.30 m                                                                                                                            
  18.6, CH~2~       1.64 m                                                                                                          
  13.8, CH~3~       0.95 t (7.5)                                                                                                    
  3-OAc             169.6, C                                                           169.5, C                      169.4, C       
  22.4, CH~3~       2.12 s            22.4, CH~3~    2.07 s             22.4, CH~3~    2.07 s                                       
  6-OMe             57.0, CH~3~       3.34 s                                                                                        
  6-OAc                                                                                                                             
  8-OAc                                                                                                                             
  12-OAc                                             170.0, C                                                        170.3, C       
  21.2, CH~3~       2.14 s            21.5, CH~3~    2.06 s                                                                         

^a^ ^13^C and ^1^H spectra recorded at 100 and 400 MHz in CDCl~3~; ^b^ ^13^C and ^1^H spectra recorded at 125 and 500 MHz in CDCl~3~; ^c^ Deduced from DEPT; ^d^ *J* values (Hz) in parentheses; ^e^ Broad signal.

The new metabolite krempfielin K (**2**) was found to have the molecular formula C~26~H~42~O~8~ and six degrees of unsaturation, as indicated from the HRESIMS. The IR absorptions at ν~max~ 3444 and 1732 cm^−1^ revealed the presence of hydroxy and ester carbonyl functionalities. The ^13^C carbons spectral data ([Table 1](#marinedrugs-11-02741-t001){ref-type="table"}) were assigned by the assistance of DEPT spectrum to six methyls (including one acetate methyl δ~C~ 21.2), five sp^3^ methylenes, one sp^2^ methylene, nine sp^3^ methines (including five oxymethines), two sp^3^ and three sp^2^ quaternary carbons (including two ester carbonyls). The NMR spectroscopic data of **2** ([Table 1](#marinedrugs-11-02741-t001){ref-type="table"}) showed the presence of one 1,1-disubstituted double bond (δ~C~ 105.0, CH~2~ and 145.3, C; δ~H~ 5.23, s and 5.04, s, each 1H). Two ester carbonyls (δ~C~ 172.6 and 170.0) were assigned from the ^13^C NMR spectrum and were HMBC correlated with the methylene (δ~H~ 2.30 m and 2.22 m, each 1H) of an *n*-butyrate and those of an acetate methyl (δ~H~ 2.14, s, 3H), respectively. Therefore, the remaining three degrees of unsaturation identified compound **2** as a tricyclic molecule. ^1^H-^1^H COSY and HMBC correlations ([Figure 1](#marinedrugs-11-02741-f001){ref-type="fig"}) were further used to establish the molecular skeleton of **2**. The COSY experiment assigned five isolated consecutive proton spin systems. Above evidences and HMBC correlations from H-2 and H-6 (δ~H~ 3.58 and 3.68) to C-6 and C-2 (δ~C~ 70.1 and 80.9), respectively, implied the presence of an ether linkage between C-2 and C-6, and suggested that **2** is an 2,6-ether linked eunicellin-based diterpenoid \[[@B1-marinedrugs-11-02741],[@B26-marinedrugs-11-02741]\]. Furthermore, the acetoxy group attaching at C-12 was confirmed from the HMBC correlations from H-12 (δ~H~ 5.29) and acetate methyl protons (δ~H~ 2.14) to the carbonyl carbon appearing at 170.0 (C). Thus, the remaining one *n*-butyryloxy group had to be positioned at C-3, an oxygen-bearing quaternary carbon resonating at δ 83.8 ppm. On the basis of above analysis, the planar structure of **2** was established. The relative structure of **2** was elucidated by the analysis of NOESY correlations, as shown in [Figure 2](#marinedrugs-11-02741-f002){ref-type="fig"}. The observation of the NOE interactions between H-1 and H-6, H-8 and H-10; H-10 and both H-8 and H-12, revealed that they are all β-oriented. Also, the correlations between H-2 and H-9, H-14 and H~3~-15; H-9 and H~3~-16 suggested that of all of H-2, H-9, H-14, H~3~-15 and H~3~-16 are α-oriented. The relative configuration of **2** was thus established. The highly oxygenated pattern of **2** at C-2, C-3, C-6, C-7, C-8, C-9 and C-12 is rare in known eunicellins.

![Selected ^1^H-^1^H COSY (▬) and HMBC (→) correlations of **2**--**4**.](marinedrugs-11-02741-g001){#marinedrugs-11-02741-f001}

Krempfielin L (**3**) showed the molecular ion peak \[M + Na\]^+^ at *m*/*z* 419.2407 in the HRESIMS and established a molecular formula of C~22~H~36~O~6~, implying five degrees of unsaturation. The IR absorptions at ν~max~ 3419 and 1734 cm^−1^ revealed the presence of hydroxy and ester carbonyl functionalities. The ^13^C NMR spectrum of **3** showed signals of 22 carbons ([Table 1](#marinedrugs-11-02741-t001){ref-type="table"}), which were characterized by the DEPT spectrum as five methyls (including one acetate methyl), five methylenes (including one sp^2^ methylene), eight methines (including four oxygenated carbons), and four quaternary carbons (including one ester carbonyl and one sp^2^ quaternary carbon of an olefin). The ^1^H and ^13^C NMR spectral data of **3** ([Table 1](#marinedrugs-11-02741-t001){ref-type="table"}) also showed the presence of one acetoxy group (δ~H~ 2.07, s, 3H; δ~C~ 22.4, CH~3~ and 169.5, C). The remaining three degrees of unsaturation again identified **3** as a tricyclic diterpenoid. The molecular framework was established by ^1^H-^1^H COSY and HMBC correlations ([Figure 1](#marinedrugs-11-02741-f001){ref-type="fig"}). Comparison of the NMR data of **3** with those of the known compound sclerophytin E \[[@B27-marinedrugs-11-02741]\] revealed that **3** is the C-12 hydroxylated derivative of sclerophytin E. The stereochemistry of compound **3** was determined by the NOESY spectrum as shown in [Figure 2](#marinedrugs-11-02741-f002){ref-type="fig"}.

![Key NOESY correlations for **2** and **3**.](marinedrugs-11-02741-g002){#marinedrugs-11-02741-f002}

The HRESIMS (*m*/*z* 461.2518 \[M + Na\]^+^) of krempfielin M (**4**) established the molecular formula of C~24~H~38~O~7~. The ^1^H and ^13^C NMR spectral data of **4** ([Table 1](#marinedrugs-11-02741-t001){ref-type="table"}) revealed that the structure of metabolite **4** should be similar to that of **3**, as the ^1^H NMR spectral data of **4** are almost identical with those of **3** except for the presence of one additional acetyl group (δ~H~ 2.06, s, 3H) in **4**. Furthermore, the placement of an acetoxy group at C-12 was established by the HMBC experiment which showed correlations from an oxymethine (δ~H~ 5.44, H-12) and acetate methyl (δ~H~ 2.06) to the ester carbonyl carbon appearing at δ~C~ 170.3 (C) ([Figure 1](#marinedrugs-11-02741-f001){ref-type="fig"}). The NOE correlations of **4** also showed that the stereochemistry of this metabolite is identical with that of **3**. Thus the structure of metabolite **4** was determined.

The *in vitro* anti-inflammatory effects of the diterpenoids **1**--**6** were tested by examining the inhibitory activity of these compounds toward the release of elastase in *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (FMLP/CB)-induced human neutrophils cells ([Table 2](#marinedrugs-11-02741-t002){ref-type="table"}). At a concentration of 10 μM, all of these compounds could not significantly reduce the expression of superoxide anion, relative to the control cells stimulated with FMLP/CB only. At the same concentration, compounds **2** and **4** were found to effectively inhibit the elastase release (45.51 ± 2.69% and 27.30 ± 5.42% inhibition, respectively) in the same FMLP/CB-stimulated cells.

marinedrugs-11-02741-t002_Table 2

###### 

Effect of pure compounds on elastase release in FMLP/CB-induced human neutrophils.

  Compound   Elastase                
  ---------- -------------- -------- ------
  **1**      19.42 ± 7.89   \*       \>10
  **2**      45.51 ± 2.69   \*\*\*   \>10
  **3**      18.67 ± 5.75   \*       \>10
  **4**      27.30 ± 5.42   \*\*     \>10
  **5**      −0.32 ± 0.81            \>10
  **6**      6.15 ± 3.42             \>10

Percentage of inhibition (Inh%) was measured at 10 μM. Results are presented as mean ± S.E.M. (*n* = 3 or 4); **\*** *p* \< 0.05, **\*\*** *p* \< 0.01 and **\*\*\*** *p* \< 0.001 compared with the control value.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Melting point was determined using a Fisher-Johns melting point apparatus. Optical rotations were measured on a JASCO P-1020 polarimeter. IR spectra were recorded on a JASCO FT/IR-4100 infrared spectrophotometer. ESIMS were obtained with a Bruker APEX II mass spectrometer. The NMR spectra were recorded either on a Varian UNITY INOVA-500 FT-NMR and a Varian 400MR FT-NMR. Silica gel (Merck, 230--400 mesh) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical thin layer chromatography (TLC). High performance liquid chromatography was performed on a Hitachi L-7100 HPLC apparatus with an octadecylsilane (ODS) column (250 × 21.2 mm, 5 μm).

3.2. Animal Material
--------------------

*C. krempfi* was collected by hand using scuba off the coast of Penghu islands of Taiwan in June 2008, at a depth of 5--10 m, and stored in a freezer until extraction. A voucher sample (specimen No. 200806CK) was deposited at the Department of Marine Biotechnology and Resources, National Sun Yat-sen University*.*

3.3. Extraction and Separation
------------------------------

The octocoral (1.1 kg fresh wt) was collected and freeze-dried. The freeze-dried material was minced and extracted exhaustively with EtOH (3 × 10 L). The EtOH extract of the frozen organism was partitioned between CH~2~Cl~2~ and H~2~O. The CH~2~Cl~2~-soluble portion (14.4 g) was subjected to column chromatography on silica gel and eluted with EtOAc in *n*-hexane (0%--100% of EtOAc, stepwise) and then further with MeOH in EtOAc with increasing polarity to yield 41 fractions. Fraction 28, eluted with *n*-hexane--EtOAc (1:2), was rechromatoraphed over a reversed-phase column (RP-18) using acetone--H~2~O (10:1) as the mobile phase to afford six subfractions (A1--A6). Subfraction A3 was repeatedly separated by reverse phase HPLC (CH~3~CN--H~2~O, 1.4:1.1) to afford compound **1** (2.6 mg). Fraction 31, eluted with *n*-hexane--EtOAc (1:10), was rechromatoraphed over a silica gel open column using *n*-hexane--acetone (3:1) as the mobile phase to afford eight subfractions (B1--B8). Subfraction B5 separated by reverse phase HPLC (CH~3~CN--H~2~O, 1:1 to 1:1.6) to afford compounds **2** (5.1 mg), **3** (2.8 mg), **5** (52.3 mg) and **6** (13.4 mg). Subfraction B6 by reverse phase HPLC (CH~3~CN--H~2~O, 1:1.5) to afford compounds **4** (8.4 mg).

### 3.3.1. Krempfielin J (**1**)

Colorless oil; \[α\]^23^~D~ = +52 (*c* 0.85, CHCl~3~); IR (neat) ν~max~ 3479, 2958, 2930, 2872, 1737, 1644, 1463, 1369, 1244, and 1100 cm^−1^; ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-11-02741-t001){ref-type="table"}; ESIMS *m*/*z* 417 \[M + Na\]^+^; HRESIMS *m*/*z* 417.2616 \[M + Na\]^+^ (calcd. for C~23~H~38~O~5~Na, 417.2617).

### 3.3.2. Krempfielin K (**2**)

White powder; mp 162--163 °C; \[α\]^25^~D~ = −58 (*c* 1.5, CHCl~3~); IR (neat) ν~max~ 3444, 2963, 1731, 1651, 1464, 1380, 1240, 1177, 1087, and 1045 cm^−1^; ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-11-02741-t001){ref-type="table"}; ESIMS *m*/*z* 505 \[M + Na\]^+^; HRESIMS *m*/*z* 505.2780 \[M + Na\]^+^ (calcd. for C~26~H~42~O~8~Na, 505.2777).

### 3.3.3. Krempfielin L (**3**)

Colorless oil; \[α\]^25^~D~ = +26 (*c* 0.8, CHCl~3~); IR (neat) ν~max~ 3419, 2958, 1734, 1457, 1369, 1246, 1063 and 1026 cm^−1^; ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-11-02741-t001){ref-type="table"}; ESIMS *m*/*z* 419 \[M + Na\]^+^; HRESIMS *m*/*z* 419.2407 \[M + Na\]^+^ (calcd. for C~22~H~36~O~6~Na, 419.2409).

### 3.3.4. Krempfielin M (**4**)

Colorless oil; \[α\]^25^~D~ = +24 (*c* 2.4, CHCl~3~); IR (neat) ν~max~ 3452, 2960, 1736, 1435, 1370, 1243, 1199, 1075, and 1024 cm^−1^; ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-11-02741-t001){ref-type="table"}; ESIMS *m*/*z* 461 \[M + Na\]^+^; HRESIMS *m*/*z* 461.2518 \[M + Na\]^+^ (calcd. for C~24~H~38~O~7~Na, 461.2515).

3.4. *In Vitro* Anti-Inflammatory Assay---Superoxide Anion Generation and Elastase Release by Human Neutrophils
---------------------------------------------------------------------------------------------------------------

Human neutrophils were obtained by means of dextran sedimentation and Ficoll centrifugation. Measurements of superoxide anion generation and elastase release were carried out according to previously described procedures \[[@B28-marinedrugs-11-02741],[@B29-marinedrugs-11-02741]\]. LY294002, a phosphatidylinositol-3-kinase inhibitor, was used as a positive control for inhibition of superoxide anion generation and elastase release with IC~50~ values of 1.88 ± 0.45 and 4.12 ± 0.92 μM, respectively. Briefly, superoxide anion production was assayed by monitoring the superoxide dismutase-inhibitable reduction of ferricytochrome c. Elastase release experiments were performed using MeO-Suc-Ala-Ala-Pro-Val-*p*-nitroanilide as the elastase substrate \[[@B30-marinedrugs-11-02741]\].

4. Conclusions
==============

New eunicellin-based diterpenoids were isolated together with known ones from the soft coral *Cladiella krempfi.* Compounds **2** and **4** could significantly inhibit the release of elastase in FMLP/CB-induced human neutrophils. Thus, compounds **2** and **4**, in particular **2**, could be promising anti-inflammatory agents and may warrant further biomedical investigation.
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